Selected highlights from the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Amsterdam, The Netherlands
26-28 October 2022
62 slides with notes
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada Read More
Includes a comparison of anti-CD20 therapies (rituximab, ocrelizumab, ofatumumab), depth and duration of B cell suppression, time to B cell reconstitution, and current data on reduced-dose regimens, extended-interval dosing and personalized dosing.
Selected highlights from ECTRIMS 2021
Virtual Congress – 13-15 October 2021
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada
Provides information on SPMS diagnosis, active and progressive sub-phenotypes, time to SPMS in historical and contemporary cohorts, age and EDSS score as predictors of SPMS, and patients’ symptom that may herald the transition to SPMS.
Provides information on CD20, binding epitopes of anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, ublituximab) and the effects of anti-CD20 MAbs in multiple sclerosis. Includes slides explaining antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).